Download PDF
Pharmacopsychiatry 2017; 50(01): 38-40
DOI: 10.1055/s-0042-110492
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Use of Paliperidone Palmitate Throughout a Schizoaffective Disorder Patient’s Gestation Period

F. J. Zamora Rodríguez
1   Physician Specialist (F.E.A.) in Psychiatry, Equipo de Salud Mental de Zafra (Badajoz), Spain
,
C. Benítez Vega
2   Midwife, Centro de Salud de Zafra (Badajoz), Spain
,
M. R. Sánchez-Waisen Hernández
3   Complejo Hospitalario Torrecárdenas, Almería, Spain
,
J. A. Guisado Macías
4   Hospital Infanta Cristina, Departamento de Psiquiatría, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain
,
F. J. Vaz Leal
5   Faculty of Medicine, Equipo de Salud Mental de Valdepasillas, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain
› Author Affiliations
Further Information

Publication History

received 29 December 2015
revised 05 June 2016

accepted 08 June 2016

Publication Date:
14 July 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Paliperidone palmitate treatment of schizophrenia or schizoaffective disorder is effective and well tolerated, but there is almost no data on its safety during pregnancy.

Case report: An analysis is made of the safety and tolerability of paliperidone palmitate treatment throughout the gestation period in a 34-year-old patient diagnosed with schizoaffective disorder.

Discussion: Paliperidone palmitate treatment throughout the gestation period was safe and well tolerated by both mother and foetus, there being no malformations or other perinatal complications in the newborn to date.

Key words

schizoaffective disorder - pregnancy - paliperidone palmitate - safety - antipsychotic treatment
 

  • References

  • 1 Kim S, Solari H, Weiden PJ et al. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. Patient Prefer Adherence 2012; 6: 533-545
    PubMedGoogle Scholar
  • 2 Oyebode F, Rastogi A, Berrisford G et al. Psychotropics in pregnancy: safety and other considerations. Pharmacology and therapeutics 2012; 135: 71-77
    CrossrefPubMedGoogle Scholar
  • 3 Vigod SN, Gomes T, Wilton AS et al. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ 2015; 350: h2298
    CrossrefPubMedGoogle Scholar
  • 4 Wichman CL. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health 2009; 12: 53-57
    CrossrefPubMedGoogle Scholar
  • 5 Özdemir AK, Pak SC, Canan F et al. Paliperidone palmitate use in pregnancy in a woman with schizophrenia. Arch Womens Ment Health 2015; 739-740 DOI: 1007/s00737-014-0496-6.
    PubMedGoogle Scholar
  • 6 Fernández I, Álvarez E. Estudio Llevant. El desarrollo psicomotor de 1.702 niños de 0 a 24 meses. Tesis Doctoral, Universidad de Barcelona 1989
    PubMed
  • 7 Iceta A, Yoldi ME. Psychomotor development of the child and its evaluation in primary care. An Sist Sanit Navar 2002; 25 (Suppl. 02) 35-43
    PubMedGoogle Scholar
  • 8 Xeplion® Data Sheet Janssen-Cilag International, 2011, updated 2015
    PubMed
  • 9 Paisán L, Sota I, Muga O et al. El recién nacido de bajo peso. Protocolos Diagnóstico Terapeúticos de la Asociación Española de Pediatría: Neonatología 2008; 78-84
    PubMedGoogle Scholar
  • 10 Cohen LS, Viguera AC, McInerney KA et al. Reproductive safety of second-generation antipsychotics: current data rrom the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry 2016; 173: 263-270
    CrossrefPubMedGoogle Scholar
  • 11 Kulkarni J, Storch A, Baraniuk A et al. Antipsychotic use in pregnancy. Expert Opin Pharmacother 2015; 16: 1335-1345
    CrossrefPubMedGoogle Scholar